AstraZeneca's new lab to host key research work

RELATED NEWS AstraZeneca inaugurates R&D lab in Bangalore AstraZeneca expanding R&D operation in India ALSO READ See latest News about AstraZeneca See previous management interviews See what other Experts & Brokerages are saying about AstraZeneca AstraZeneca BSE | NSE 29/05/12 Are Mutual Funds betting on AstraZeneca?

Overall target

The Anglo-Swedish drug major has an overall target of developing over 20 candidate drugs this year. The four PR&D centres work in tandem and share their resources and work. The Bangalore centre - set up at nearly 25 per cent of the Western cost but of the same quality - has handled work related to oncology and anti-infectives from other centres and it will move on to the tuberculosis drug candidate once it is arrived at, according to Dr Lundberg.

The Indian research subsidiary, AstraZeneca India P Ltd, which includes the PR&D centre, is doing AstraZeneca's 'largest drug-hunting mission' - to discover a novel, short-duration drug for tuberculosis. It expects to reach the potential drug stage by 2009.

The process PR&D centre will have the capability to produce 3-5 kg of active drug ingredients.

Taken from Business Line

thehindubusinessline.in